Case Study
K Pro Multi-omic Reports
Bespoke K Pro reports powered by multimodal patient data

K Pro
AI Scientist
Trusted by Boehringer Ingelheim
MOSAIC analysis report used to inform target prioritisation
Owkin’s reports identify better patient subgroup biomarkers.
Commission a report analysing patient heterogeneity and expression patterns of relevant genes in 10 cancer indications.
Owkin’s reports - through K Pro - offer better biological understanding than competitors’ as they retain spatial biological information, unlike reports only relying on bulk RNA sequencing datasets.
Go beyond basic tumour-level target expression. Use our deeply differentiated insights to support data-driven hypotheses and optimize your asset positioning.

Owkin’s proprietary MOSAIC multimodal data gives you what simple bulk RNA can’t
- Identify biomarkers for patient selection that are informed by spatial contexts - find biomarkers for the best responder populations.
- See tumour heterogeneity at single cell level and explore the spatial organization of the tumour microenvironment - ensure target cells or spatial regions express your gene of interest.
- Stratify your patient population with highly detailed, expert-curated, clinical data (including line of treatment, overall clinical outcome, and longitudinal data) - refine your clinical trial by clinico-pathological features.

Our agentic AI enhances the data further
- Owkin’s Pathology Explorer augments histology slides (H&E) for individual cell-type quantification and analysis.
- State-of-the-art deconvolution algorithms use information extracted from single-cell patient data to increase the resolution of spatial transcriptomic slides to single-cell level.
- Spatial organisation prediction models highlight the different spatial cellular regions within the tumour (e.g. stromal, tumour core, tumour front).
